Sangamo Therapeutics (SGMO)

$0.11 -0.07 (-37.27%)
Market Cap 73.58M
Revenue (ttm) 39.55M
Net Income (ttm) -122.93M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -310.82%
Debt to Equity Ratio 0.00
Volume 44,541,699
Avg Vol 10,731,998
Day's Range N/A - N/A
Shares Out 414.28M
Stochastic %K 4%
Beta 1.04
Analysts Sell
Price Target $3.75

Company Profile

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; small fiber neuropathy for chronic neuropathic pain, and prion disease; Phase 1/2 clinical trial to evaluate the...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 970 6000
Address:
501 Canal Blvd, Richmond, United States
Rodmon77
Rodmon77 May. 19 at 9:06 PM
$SGMO Top Holders
0 · Reply
epet3
epet3 May. 19 at 7:59 PM
$SGMO ITS HAPPENING
2 · Reply
boomshiva
boomshiva May. 19 at 7:53 PM
$SGMO Nice to see green on a day mostly of red.
1 · Reply
Mr_Mxyzptlk
Mr_Mxyzptlk May. 19 at 7:47 PM
$SGMO I'm starting to feel like Captain Quint...slowly clicking into the fish fighting chair.....something is under the surface....
1 · Reply
Scooter0732
Scooter0732 May. 19 at 7:18 PM
$SGMO Realistically, the most likely outcome for Sangamo—assuming Sandy isn't lying about ST-920—is a structured partnership. Pharma would provide modest upfront ~$75–100M along with standard development/commercial economics. The key dynamic would likely be an embedded option structure, where the partner can acquire Fabry program outright at in the several hundred million dollar range if approval + sales come to fruition. This would allow pharma to limit upfront while locking access to the asset. In that scenario, Sangamo would preserve the broader platform and remain operational, but much of the long-term upside associated with ST-920/Fabry would be stripped from the company because they are distressed.
1 · Reply
jlemx
jlemx May. 19 at 5:35 PM
$SGMO Contrary to what some people have said on this forum, Ambetter Health Centene is preparing the insurance plan to cover Sangamo's Fabry therapy even before FDA approval! That's huge.
3 · Reply
Patrick2343
Patrick2343 May. 19 at 5:23 PM
$SGMO I am not sure what he expects the science is not relevant to investors anymore. Most people think of this as a dead company and until or if they bring in money it will trade like this til they go broke. Phoenix Biotech @BiotechAnalysst · 1h 600K bid .116 $SGMO ultra low penny flipping bullshit trades all day so pathetic
0 · Reply
Patrick2343
Patrick2343 May. 19 at 4:55 PM
$SGMO If they could sell this for .75 cents at this point they should jump on it. Sandy did so much damage a fire sale is likely best case now.
0 · Reply
cheapostock
cheapostock May. 19 at 3:51 PM
$SGMO 10c seems to be floor!!! will add more if this stays low... wait until mid Jun!
2 · Reply
JimiJoJeeter
JimiJoJeeter May. 19 at 3:27 PM
$SGMO America's Chinese biotech question: A road to riches or ruin? https://share.google/OBOcJHKvhbYmVA2Kl
1 · Reply
Latest News on SGMO
No data available.
Rodmon77
Rodmon77 May. 19 at 9:06 PM
$SGMO Top Holders
0 · Reply
epet3
epet3 May. 19 at 7:59 PM
$SGMO ITS HAPPENING
2 · Reply
boomshiva
boomshiva May. 19 at 7:53 PM
$SGMO Nice to see green on a day mostly of red.
1 · Reply
Mr_Mxyzptlk
Mr_Mxyzptlk May. 19 at 7:47 PM
$SGMO I'm starting to feel like Captain Quint...slowly clicking into the fish fighting chair.....something is under the surface....
1 · Reply
Scooter0732
Scooter0732 May. 19 at 7:18 PM
$SGMO Realistically, the most likely outcome for Sangamo—assuming Sandy isn't lying about ST-920—is a structured partnership. Pharma would provide modest upfront ~$75–100M along with standard development/commercial economics. The key dynamic would likely be an embedded option structure, where the partner can acquire Fabry program outright at in the several hundred million dollar range if approval + sales come to fruition. This would allow pharma to limit upfront while locking access to the asset. In that scenario, Sangamo would preserve the broader platform and remain operational, but much of the long-term upside associated with ST-920/Fabry would be stripped from the company because they are distressed.
1 · Reply
jlemx
jlemx May. 19 at 5:35 PM
$SGMO Contrary to what some people have said on this forum, Ambetter Health Centene is preparing the insurance plan to cover Sangamo's Fabry therapy even before FDA approval! That's huge.
3 · Reply
Patrick2343
Patrick2343 May. 19 at 5:23 PM
$SGMO I am not sure what he expects the science is not relevant to investors anymore. Most people think of this as a dead company and until or if they bring in money it will trade like this til they go broke. Phoenix Biotech @BiotechAnalysst · 1h 600K bid .116 $SGMO ultra low penny flipping bullshit trades all day so pathetic
0 · Reply
Patrick2343
Patrick2343 May. 19 at 4:55 PM
$SGMO If they could sell this for .75 cents at this point they should jump on it. Sandy did so much damage a fire sale is likely best case now.
0 · Reply
cheapostock
cheapostock May. 19 at 3:51 PM
$SGMO 10c seems to be floor!!! will add more if this stays low... wait until mid Jun!
2 · Reply
JimiJoJeeter
JimiJoJeeter May. 19 at 3:27 PM
$SGMO America's Chinese biotech question: A road to riches or ruin? https://share.google/OBOcJHKvhbYmVA2Kl
1 · Reply
Wischmop
Wischmop May. 19 at 1:37 PM
$SGMO Good research, a good precedent, and interesting personnel connections... the parameters of SGMO are remarkably similar... this at least shows that the last ones involved aren't building castles in the air, but rather have a solid foundation for their investment decision.
1 · Reply
biotech
biotech May. 19 at 1:26 PM
$SGMO has been granted Fabry gene therapy #patent today
1 · Reply
BoloTheGrey
BoloTheGrey May. 19 at 1:19 PM
$SGMO
0 · Reply
Wischmop
Wischmop May. 19 at 12:52 PM
$SGMO 1. March/April: Sensational long-term eGFR data and the FDA's decision to forgo Phase 3. 2. First quarter: UBS, Balyasny, and Bank of America quietly build up multi-million dollar positions during the Nasdaq sell-off. 3. May 18 (Yesterday): A top-three US insurer establishes its reimbursement policy for the drug even before the BLA application is finalized. I'd say that's quite a lot of effort for a dead company…
2 · Reply
biotech
biotech May. 19 at 6:38 AM
Effective June 1, 2026: Pharmacy and Biopharmacy Policies 05/18/26 the following policies are effective on June 1, 2026, at 12:00AM: $SGMO Fabry GT Isaralgagene Civaparvovec
0 · Reply
Scooter0732
Scooter0732 May. 19 at 2:16 AM
$SGMO Check out the Adverum buy by Lilly a few months ago, pretty good read through to SGMO. Distressed price + large CVR got it done. CTO from adverum came from SGMO and posted on LinkedIn he’s a part of the leadership team for LLY’s regenerative medicine unit now. Ixo-vec had more safety issues and was P3 ready for wet AMD. GT isn’t dead even if the market won’t fund it anymore.
0 · Reply
Wischmop
Wischmop May. 18 at 8:59 PM
$SGMO Wow, that's really interesting information. You're very well-informed. But it's true, they bought in before SGMO changed hands. They probably already knew the quality of the data in advance, but not when that data would lead to a deal. So they bought in beforehand at the higher prices. The fact that they bought in the first quarter is one important signal. But the much more important signal is what they haven't done since then: namely, nothing, they're holding... I hope they're having pleasant conversations with acquaintances and friends in investment bankers in their small, elite circles, and exchanging a few favors...
1 · Reply
Top_Dog_Pro_Trader
Top_Dog_Pro_Trader May. 18 at 3:57 PM
$SGMO all true Omar/ Wishmop… the difference here is I don’t recall this number of institutions taking a stake in a Company post delisting. They are all interconnected in the financial markets and may know of $$$ being raised for a deal IMO!
2 · Reply
Wischmop
Wischmop May. 18 at 2:37 PM
$SGMO They're doing the same thing as us: picking up the crumbs left behind by others who were forced to sell due to the stock market change. It all sounds good at first, but it remains risky. We'll have our first insights on June 9th to see if they've managed to achieve anything constructive. But still: • UBS Group AG: Increased stake by 150% to 2.57 million shares (filed in early May). • Balyasny Asset Management: New entry with 5.00 million shares (filed today). • Bank of America: New entry/increase with 1.70 million shares. Together, these three alone hold almost 9.3 million shares. But you have to read the numbers correctly; ultimately, only small sums are being invested. They're doing the same thing as us: placing an asymmetric bet with a low stake and extreme profit potential. It doesn't matter to me whether it's a partnership deal or a complete sale, even though the latter would simplify things considerably for shareholders. The last sentence is for Patrick
1 · Reply
biotech
biotech May. 18 at 1:54 PM
$SGMO Bank of America adding 1.7M shares od $SGMO
0 · Reply
biotech
biotech May. 18 at 1:53 PM
$SGMO $SGMO BALYASNY ASSET MANAGEMENT new 5M shares position
0 · Reply